About This Event

Abivax (Nasdaq and Euronext: ABVX), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Marc de Garidel, CEO and Interim Board Chair, rings the Closing Bell.